e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions
NCT02087293 is an interventional trial sponsored by Brigham and Women's Hospital. As of 18 Nov 2026, it has a status the registry marks as unknown. It studies Depression, Diabetes and 2 more conditions. The registry lists an enrollment of 38,400 participants at 1 site in 1 country. The registry lists a start date of 30 Jun 2013 and a primary completion date of 31 Mar 2015.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT02087293 |
| Status | Unknown |
| Study type | Interventional trial |
| Lead sponsor | Brigham and Women's Hospital |
| Enrollment | 38,400 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Depression, Diabetes, Hypertension and Insomnia |
| Start | 30 Jun 2013 |
| Primary completion | 31 Mar 2015 |
| Study completion | 31 Aug 2016 |
| Last update posted | 4 Aug 2015 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Gordon Schiff, MD
Brigham and Women's Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Brigham and Women's Hospital
Boston
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Questions about NCT02087293
Each answer restates registry values shown on this page.
What is NCT02087293?
NCT02087293 is an interventional trial sponsored by Brigham and Women's Hospital. It studies Depression, Diabetes and 2 more conditions.
Who leads NCT02087293?
The registry names Gordon Schiff, MD (principal investigator, Brigham and Women's Hospital) as the overall official.
Where does NCT02087293 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
When is NCT02087293 expected to complete?
The registry lists a primary completion date of 31 Mar 2015 and a study completion date of 31 Aug 2016. The sponsor last updated the record on 4 Aug 2015.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.